What are the latest developments in stem cells and regenerative medicine in this first week of 2017 and right before the end of the past year? Here are some of the headlines and papers that have popped up that seem notable or surprising. Be sure to also check out our stem cell & regenerative medicine […]
TGIF: Week’s Stem Cell Headlines, Papers, & Resources Read More »
Below are the 2016 stem cell predictions I made last year and their status now color-coded near year’s end. Green is right, orange is mixed bag, and red is flat out wrong. Overall, I did better than most past years with only having entirely blown it on four. Stay tuned later this week for my 2017 predictions,
Grading my stem cell predictions for 2016: how’d I do? Read More »
Recently I had the opportunity to talk with the leadership of Asterias, a California biotech doing exciting clinical research using stem cells as the basis for treatment of spinal cord injury. The interview covers the past (Geron patients), present, and future. I spoke with Asterias President and CEO Stephen Cartt and CMO Edward Wirth. How
Asterias interview: stem cell spinal cord injury trials advance Read More »
I received a score of great nominations for the Stem Cell Person of the Year 2016 Award and have briefly described the twenty nominees below. The point of the award is to honor the top positive stem cell leader who specifically thinks outside the box and takes risks. I’ve started an on-line vote where you can vote once per day for
20 Nominees for Stem Cell Person of the Year 2016 Award Read More »
The 21st Century Cures Act has some important provisions that would impact the stem cell and regenerative medicine field. What is driving these efforts is a widespread sense that the status quo of regenerative medicine oversight isn’t working very well. I’m talking with key stakeholders and still trying to sort out my thoughts on the
Perspectives on Cures Act stem cell provisions possible benefits & risks Read More »
The money behind a piece of legislation can provide unique insights into the back story and this is definitely true for the REGROW Act that would reduce FDA oversight of the investigational use of stem cells in patients. Senator Mark Kirk of Illinois, who is facing probable defeat next week in his reelection bid according to
REGROW Act, Mark Kirk Lobbying & Contributions Yield Stem Cell Surprises Read More »
By Samantha Yammine, PhD Candidate in Derek van der Kooy’s lab at the University of Toronto. See tweets live from #TMM2016 via @SamanthaZY here. Last week, 430 Canadian scientists, trainees, industry professionals, science communicators and international guests gathered in the picturesque ski town of Whistler, British Columbia for the annual Till & McCulloch meeting (TMM).
If you rewind the stem cell clock several years, the big news in the stem cell clinic arena was dominated for quite some time by a single stem cell clinic called Celltex in Texas in part because their most famous customer was Governor (at that time) Rick Perry. You can read the many past posts I’ve
Rick Perry’s Paid Board Position at Controversial Stem Cell Clinic Celltex Read More »
Happy Stem Cell Day! It is a tumultuous time for the stem cell and regenerative medicine fields, but despite this there are concrete reasons for optimism on this Stem Cell Awareness Day. I’ve listed my top 10 below. What else gives you a sense of optimism? You can also check out CIRM’s nifty stem cell
Reasons for optimism on Stem Cell Day 2016 Read More »
South Africa is facing a stem cell scandal related to what a health policy news outlet called Spotlight there characterizes as illegal experiments by ReGenesis Biotechnologies, the company at the heart of the controversy. It had a contract with a governmental health provider agency, now apparently suspended. The report begins this way: “The Medicines Control Council
South Africa grapples with “illegal” stem cell experiment scandal Read More »